Join Growin Stock Community!

台康生技6589.TW Overview

TW StockBiotech. & Medical
(No presentation for 6589)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

台康生技（6589）Overall Performance

台康生技（6589）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

台康生技（6589） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

台康生技（6589）Key Information

台康生技（6589）Profile

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. EirGenix Inc. was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.

台康生技（6589）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
19.78
PB Ratio
2.19
Price-to-FCF
88.64
METRIC
VALUE
vs. INDUSTRY
Gross Margin
17.96%
Net Margin
-75.39%
Revenue Growth (YoY)
-17.59%
Profit Growth (YoY)
-46.21%
3-Year Revenue Growth
-12.05%
3-Year Profit Growth
-57.85%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
19.78
PB Ratio
2.19
Price-to-FCF
88.64
Gross Margin
17.96%
Net Margin
-75.39%
Revenue Growth (YoY)
-17.59%
Profit Growth (YoY)
-46.21%
3-Year Revenue Growth
-12.05%
3-Year Profit Growth
-57.85%
default symbol

6589

台康生技

60.40D

-1.32%

(-0.01)

  • When is 6589's latest earnings report released?

    The most recent financial report for 台康生技 (6589) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6589's short-term business performance and financial health. For the latest updates on 6589's earnings releases, visit this page regularly.

  • What is the operating profit of 6589?

    According to the latest financial report, 台康生技 (6589) reported an Operating Profit of -179.6M with an Operating Margin of -78.43% this period, representing a growth of 26.95% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6589's revenue growth?

    In the latest financial report, 台康生技 (6589) announced revenue of 229M, with a Year-Over-Year growth rate of -7.74%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6589 have?

    At the end of the period, 台康生技 (6589) held Total Cash and Cash Equivalents of 2.9B, accounting for 0.28 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6589 go with three margins increasing?

    In the latest report, 台康生技 (6589) did not achieve the “three margins increasing” benchmark, with a gross margin of 14.21%%, operating margin of -78.43%%, and net margin of -26.34%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6589's profit trajectory and future growth potential.

  • Is 6589's EPS continuing to grow?

    According to the past four quarterly reports, 台康生技 (6589)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6589?

    台康生技 (6589)'s Free Cash Flow (FCF) for the period is -37.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 149.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.